Pfizer is gearing up for a consumer-driven market for obesity drugs that could match the rapid growth it experienced after introducing erectile dysfunction drug Viagra more than 20 years ago, Chief Executive Albert Bourla said on Jan. 12.
Speaking during the J.P. Morgan Healthcare Conference in San Francisco, Bourla said Pfizer underestimated how quickly patients would be willing to pay out of pocket for obesity treatments, even without insurance coverage.
